These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1101842)

  • 21. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosage and side effect comparisons betweel oral and depot fluphenazine.
    Schooler NR; Levine J
    Psychopharmacol Bull; 1977 Jul; 13(3):29-31. PubMed ID: 329328
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs and benefits of two doses of fluphenazine.
    Marder SR; Van Putten T; Mintz J; McKenzie J; Lebell M; Faltico G; May PR
    Arch Gen Psychiatry; 1984 Nov; 41(11):1025-9. PubMed ID: 6437365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment.
    Itil TM; Saletu B; Hsu W; Kiremitci N; Keskiner A
    Acta Psychiatr Scand; 1971; 47(4):440-51. PubMed ID: 4947806
    [No Abstract]   [Full Text] [Related]  

  • 26. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
    Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
    Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.
    Kane JM; Rifkin A; Quitkin F; Nayak D; Saraf K; Ramos-Lorenzi JR; Klein DF; Sachar EJ
    Psychiatry Res; 1979 Dec; 1(3):341-8. PubMed ID: 233160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA
    Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity in chronic schizophrenic patients: comparison of pimozide with fluphenazine in a double blind trial.
    Sims AC; Burnside IG
    Psychol Med; 1975 May; 5(2):161-4. PubMed ID: 1099598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study.
    Hogarty GE; McEvoy JP; Munetz M; DiBarry AL; Bartone P; Cather R; Cooley SJ; Ulrich RF; Carter M; Madonia MJ
    Arch Gen Psychiatry; 1988 Sep; 45(9):797-805. PubMed ID: 3415422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data.
    Rifkin A; Quitkin F; Klein DF
    Arch Gen Psychiatry; 1977 Oct; 34(10):1215-9. PubMed ID: 199129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low dose medication strategies in the maintenance treatment of schizophrenia.
    Kane JM
    Schizophr Bull; 1983; 9(4):528-32. PubMed ID: 6140751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timing of acute clinical response to fluphenazine.
    Levinson DF; Singh H; Simpson GM
    Br J Psychiatry; 1992 Mar; 160():365-71. PubMed ID: 1562863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.
    Marder SR; Van Putten T; Mintz J; Lebell M; McKenzie J; May PR
    Arch Gen Psychiatry; 1987 Jun; 44(6):518-21. PubMed ID: 3555385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pimozide versus fluphenazine in ambulatory schizophrenics: A 12-month comparison study.
    Donlon PT; Swaback DO; Osborne ML
    Dis Nerv Syst; 1977 Feb; 38(2):119-23. PubMed ID: 319967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate.
    Wiles D; Franklin M; Dencker SJ; Johansson R; Lundin L; Malm U
    Psychopharmacology (Berl); 1980; 71(2):131-6. PubMed ID: 6777812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.
    Hirsch SR; Gaind R; Rohde PD; Stevens BC; Wing JK
    Br Med J; 1973 Mar; 1(5854):633-7. PubMed ID: 4571196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients.
    Knights A; Okasha MS; Salih MA; Hirsch SR
    Br J Psychiatry; 1979 Dec; 135():515-23. PubMed ID: 394794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study.
    Jakovljevic M; Pivac N; Mihaljevic-Peles A; Mustapic M; Relja M; Ljubicic D; Marcinko D; Muck-Seler D
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):399-402. PubMed ID: 17126974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.